Stock listing

NASDAQ:COGT Cogent Biosciences, Inc. Stock

Home listing (NASDAQ) of Cogent Biosciences, Inc.

Follow Cogent Biosciences, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:COGT

$29.52 USD +0.01 (+0.0%)

Close on Oct 16, 2026

Since Jul 6, 2026 -25.2% · daily closes, Jul 6, 2026 – Oct 16, 2026, adjusted for splits
Day range
$28.77 – $29.98 USDOct 16, 2026
Volume
2.78M sharesOct 16, 2026
Market value
$5.12B USDAt the close on Oct 16, 2026 · price × 173.5M shares outstanding
Cogent Biosciences, Inc. logo
Ticker
NASDAQ:COGT
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

Sep 15, 2026

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results

Aug 10, 2026

Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)

Jun 30, 2026

Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress

Jun 12, 2026

Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress

Jun 12, 2026

Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

May 30, 2026

Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST

May 28, 2026

Cogent Biosciences Announces Participation in the 2026 Jefferies Global Healthcare Conference

May 27, 2026

Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress

May 12, 2026

Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results

May 5, 2026

All Cogent Biosciences, Inc. news

Financings

  • At-the-market programme of shares

    Aug 10, 2026

    Closed: US$73.6M raised

    Use of proceeds: Fund operating expenses and capital expenditures into late 2028, including through potential FDA approvals of bezuclastinib and early commercial launch

    Closed Aug 10, 2026

Read by 6ix AI from the company's releases

Decks

Cogent Biosciences, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
31 in the last 12 months · 148 in all · newest Sep 15, 2026 · oldest 2019
Decks
16 decks · latest September 2026

Where Cogent Biosciences, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:COGT · Home listing · This pageNASDAQUnited StatesUSD
BX Swiss:COGTBX SwissSwitzerlandCHF
BOATS:COGTBOATSUnited StatesUSD

Log in to ask 6ix AI your own questions about Cogent Biosciences, Inc.